Publications en collaboration avec des chercheurs de Hospital Vega Baja (15)

2023

  1. Correction: Impact of an enhanced screening program on the detection of non-AIDS neoplasias in patients with human immunodeficiency virus infection (Trials, (2021), 22, 1, (851), 10.1186/s13063-021-05777-6)

    Trials

2022

  1. Effect of PCSK9 inhibitors on remnant cholesterol and lipid residual risk: The LIPID-REAL registry

    European Journal of Clinical Investigation, Vol. 52, Núm. 12

  2. Impact of SARS-Cov-2 infection in patients with hypertrophic cardiomyopathy: results of an international multicentre registry

    ESC Heart Failure, Vol. 9, Núm. 4, pp. 2189-2198

  3. Recommendations for the management of critically ill patients with COVID-19 in Intensive Care Units

    Medicina Intensiva, Vol. 46, Núm. 2, pp. 81-89

  4. Sex Differences in Low-Density Lipoprotein Cholesterol Reduction with PCSK9 Inhibitors in Real-world Patients: The LIPID-REAL Registry

    Journal of Cardiovascular Pharmacology, Vol. 79, Núm. 4, pp. 523-529

2021

  1. Impact of an enhanced screening program on the detection of non-AIDS neoplasias in patients with human immunodeficiency virus infection

    Trials, Vol. 22, Núm. 1

2020

  1. Efficacy and Safety of Combined Therapy With Synthetic Disease-modifying Antirheumatic Drugs in Rheumatoid Arthritis: Systematic Literature Review

    Reumatologia Clinica, Vol. 16, Núm. 5P1, pp. 324-332

  2. First national survey of the diagnosis of Helicobacter pylori infection in Clinical Microbiology Laboratories in Spain

    Enfermedades Infecciosas y Microbiologia Clinica, Vol. 38, Núm. 9, pp. 410-416

2019

  1. Comparison of seven prognostic tools to identify low-risk pulmonary embolism in patients aged <50 years

    Scientific Reports, Vol. 9, Núm. 1

2012

  1. Variability in renal dysfunction defining criteria and detection methods in intensive care units: Are the international consensus criteria used for diagnosing renal dysfunction?

    Medicina Intensiva, Vol. 36, Núm. 4, pp. 264-269

2009

  1. Determinación de la concentración preventiva de mutantes resistentes a fluoroquinolonas en aislamientos clínicos de Escherichia coli productoras y no productoras de betalactamasas de espectro extendido

    Revista Espanola de Quimioterapia, Vol. 22, Núm. 1, pp. 30-33

2008

  1. Didanosine, lamivudine, and efavirenz versus zidovudine, lamivudine, and efavirenz for the initial treatment of hiv type 1 infection: Final analysis (48 weeks) of a prospective, randomized, noninferiority clinical trial, GESIDA 3903

    Clinical Infectious Diseases, Vol. 47, Núm. 8, pp. 1083-1092

  2. Staphylococcus spp. en España: Situación actual y evolución de la resistencia a antimicrobianos (1986-2006)

    Enfermedades Infecciosas y Microbiologia Clinica, Vol. 26, Núm. 5, pp. 269-277

2007

  1. Evolution of the antimicrobial resistance of Pseudomonas aeruginosa in Spain: Second National Study (2003)

    Revista Espanola de Quimioterapia, Vol. 20, Núm. 2, pp. 222-229

2006

  1. Desarrollo y validación de un cuestionario de satisfacción con el tratamiento en pacientes con artritis reumatoide

    Reumatologia Clinica, Vol. 2, Núm. 3, pp. 137-145